Tarsus Pharmaceuticals, Inc. (TARS) Dividend History

Company News

• Tarsus to Participate in Upcoming Investor Conferences

  Tarsus Pharmaceuticals announced plans to participate in several upcoming investor conferences, including the William Blair 45th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 46th Annual Global Healthcare Conference.

  GlobeNewswire Inc.
• Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

  Elanco Animal Health has sold certain future royalties and commercial milestones associated with its Xdemvy product to Blackstone for $295 million. The company will use the proceeds to reduce its debt and expects to achieve a net leverage ratio of 3.9x-4.3x EBITDA by the end of 2025.

  Benzinga

  Featured Companies: ELAN
• Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

  Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: FULC
• Rare Stock Picks In September 2023 - From 32 Discerning Analysts

  Welcome to another installment of our monthly Rare Buy article, where we highlight September investment picks you may have missed. Explore more details here.

  Seeking Alpha

  Featured Companies: ACMR ASLE CI CVCO ELV FF FMC GDTC IMMX KVHI META MOD NVGS O PANW RMD SGBX SPIR SSTK STNE UGI ULTA WBD
• Why Shares of Tarsus Pharmaceuticals Are Up Thursday

  The company's lead therapy is getting close to the finish line of FDA approval.

  The Motley Fool